EpiPen Class Action Lawsuit, Settlement, Eligibility, and How to File a Claim in 2026
The EpiPen class action lawsuit involves two major settlements totaling over $600 million to resolve allegations of illegal price hikes and antitrust violations. As of January 30, 2026, the primary consumer settlement involving Pfizer and Mylan (now Viatris) has completed its initial payout phase, but a newer $73.5 million “Direct Purchaser” settlement reached its final approval stage in mid-2025.
If you or your family purchased an EpiPen between 2011 and 2020, or if you represent a business that purchased them directly from the manufacturer through early 2025, your legal rights are still active. This guide explains the current status of these complex cases, who is eligible for the remaining funds, and the critical deadlines you must meet this year.
Specific Allegations: What Did the Lawsuit Claim?
The litigation against Mylan (Viatris) and Pfizer centered on a “pay-for-delay” scheme. Plaintiffs alleged that the companies conspired to keep lower-cost generic versions of the life-saving epinephrine injector off the market.
Specifically, the lawsuits alleged:
- Antitrust Violations: Mylan allegedly paid competitors to delay releasing generic alternatives.
- Price Fixing & Monopolization: These practices allowed the price of an EpiPen 2-Pak to skyrocket from roughly $100 to over $600 in less than a decade.
- Consumer Fraud: Plaintiffs argued that the companies used deceptive marketing and exclusionary contracts with schools and insurers to block competition.
The consolidated case, In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation (MDL No. 2785), has been litigated in the U.S. District Court for the District of Kansas.
Current Status: Settlements and Deadlines for 2026
As of January 2026, there are three distinct settlement tracks. It is vital to know which one applies to you:
| Settlement Group | Payout Amount | 2026 Status |
| Consumer Class (Pfizer & Mylan) | $609 Million | Closed. Most payouts were distributed in 2023–2024. |
| Direct Purchaser Class (Mylan) | $73.5 Million | Active. Final approval was granted in May 2025; payments are pending. |
| Direct Purchaser Class (Pfizer) | $50 Million | Active. Final approval was granted in July 2024; processing continues. |
Eligibility: Who Can Still File a Claim?
While the window for individual consumers (the “Indirect Purchasers”) largely closed in 2022, the Direct Purchaser settlements have active components in 2026:
- Direct Purchasers: If you are an entity (like a pharmacy or hospital) that purchased EpiPen or generic EpiPen products directly from Mylan or Teva between March 13, 2014, and February 6, 2025, you may still be within the processing window for the $73.5 million Mylan fund.
- Consumers with Late Claims: If you missed the original consumer deadline, some settlement administrators allow for “late-but-excused” claims if the fund has not been fully depleted. You must contact the EpiPen Class Action administrator immediately.
What You Must Know
Compensation: How Much Are the Payouts?
The amounts vary significantly based on how much you spent on EpiPens.
- Individual Consumers: Previous payouts have ranged from $20 to over $3,000, depending on the number of injectors purchased and whether the claimant had out-of-pocket costs or was reimbursed by insurance.
- Direct Purchasers: These awards are calculated pro-rata, meaning your payout is a percentage of the total settlement fund based on your total purchase volume compared to the rest of the class.
Documentation Required for Claims
In 2026, the settlement administrator is strictly enforcing documentation requirements. To verify a claim, you generally need:
- Pharmacy Records: Printouts showing the date of purchase and the amount paid.
- Insurance Explanation of Benefits (EOB): To prove out-of-pocket costs.
- Invoices: (For Direct Purchasers) Detailed purchase orders from the manufacturer.
Recent Updates as of January 2026
The most significant recent development occurred in December 2025, when the court resolved the final set of appeals regarding the Mylan Direct Purchaser settlement. This cleared the way for the $73.5 million to be distributed to eligible hospitals and pharmacies starting in early 2026. For individual consumers, while new claims are generally not being accepted, the administrator is still resolving “deficient” claims where additional proof was requested.
What to Do Next
Step 1: Check Your Claim Status
If you previously filed a claim but have not received a check, visit the official website: www.EpiPenClassAction.com. Use your Claim ID to verify if your form was flagged for “deficiency” (missing paperwork).
Step 2: Contact the Settlement Administrator
If you represent a business that purchased EpiPens directly, ensure your tax documentation is up to date with the administrator, A.B. Data, Ltd., at 1-877-221-7632. This is the only way to ensure your 2026 payout is processed.
Step 3: Monitor for Future Litigation
The success of the EpiPen settlements has paved the way for similar antitrust lawsuits against other life-saving drug manufacturers. If you use other high-cost medications, you should regularly monitor consumer protection updates to see if you are eligible for new classes.
FAQs
What is the EpiPen class action lawsuit about?
The lawsuit involves claims that Pfizer and Mylan (Viatris) engaged in anticompetitive behavior to keep generic EpiPens off the market, forcing prices up to $600 for consumers.
Is the EpiPen settlement still open in 2026?
The consumer settlement is largely closed, but the Direct Purchaser settlement for businesses and hospitals is currently in the payment distribution phase as of January 2026.
How much money do you get from the EpiPen lawsuit?
Individual payouts have ranged from under $50 to several thousand dollars, depending on purchase history. Direct purchasers may receive much larger sums based on their total volume of business.
Who is eligible for the $73.5 million Mylan settlement?
Entities that purchased EpiPen or generic EpiPen products directly from Mylan or Teva for resale between March 13, 2014, and February 6, 2025.
How do I file a claim for the EpiPen settlement?
Claims must be submitted through the official portal at www.EpiPenDPPSettlement.com (for direct purchasers) or www.EpiPenClassAction.com (for consumers).
What happens if I missed the filing deadline?
If you missed the deadline, you are generally barred from receiving a payout. However, you should check the administrator’s website for any notices regarding “supplemental” claim periods.
Last Updated: January 30, 2026
Disclaimer: This article is for informational purposes only and does not constitute legal advice. Please consult with a qualified attorney or the court-appointed settlement administrator for specific questions.
Think you might be eligible for other settlements? Stay updated on current class actions at AllAboutLawyer.com.
Stay informed, stay protected. — AllAboutLawyer.com
About the Author
Sarah Klein, JD, is a licensed attorney and legal content strategist with over 12 years of experience across civil, criminal, family, and regulatory law. At All About Lawyer, she covers a wide range of legal topics — from high-profile lawsuits and courtroom stories to state traffic laws and everyday legal questions — all with a focus on accuracy, clarity, and public understanding.
Her writing blends real legal insight with plain-English explanations, helping readers stay informed and legally aware.
Read more about Sarah